Astra Zeneca positive interim analysis of immunterapistudien Pacific can according to Swedbank’s läkemedelsanalytiker used by the market in order to find clues for the important Mystic-a study in which results are expected by the middle of 2017.
”I think the market will do in any extent. Then there is the different patient groups and different studies, so it may be enough to be careful with, but it will certainly do,” says Swedbank’s läkemedelsanalytiker Johan Unnerus to the News agency Directly.
Astra Zeneca presented in the morning positive study results from the Pacific-study for immunterapibehandlingen Imfinzi (durvalumab) for the treatment of non-small cell lung cancer who cannot have surgery.
Friday’s decision is clearly positive for Astra Zeneca who worked hard to catch up with the previous branschledarna Bristol-Myers Squibb and Merck.
The greatest weight attaches , however, the analysts against the so-called Mystic-the study, which is a combination study with Imfinza and tremelimumab for the treatment of first-line non-small cell lung cancer. It is expected that the first results of the study as mentioned earlier, in the middle of 2017.
Carnegie came in an analysis on Wednesday with a kursspann 423 to 716 dollars for Astra Zeneca course, depending on the outcome in the Mystic study, which shows the great importance the study has.
Imfinzi has of Astra Zeneca themselves also described as a cornerstone in the company’s venture in immunotherapy. In connection with the first-quarter conference call said the Astra Zeneca ceo Pascal Soriot that he sees the chance that the company becomes the leader in the treatment of first-line lung cancer. Läkemedelsbolagets the president has however, in previous presentations, toned down the importance of Imfinzi and highlighted astrazeneca’s other areas, airways, and heart/vascular and the metabolic syndrome, which is also included in astrazeneca’s core business.
Clearly, however, is that the potential for Imfinzi is significant.
Berenberg said in march 2017, Imfinzi have risk-adjusted toppförsäljning of just over $ 3.5 billion. The probability to succeed was set to 75%. Only in lung cancer is low then the sales potential of 2.5 billion dollars.
Astra Zeneca, which usually do not provide forecasts relating to the sale of individual medicinal products, submitted in connection with the strategic update 2014 an assessment of Imfinza would have a potential for a non-risk-adjusted toppförsäljning at about 6.5 billion u.s. dollars, including combination therapies.
Astra Zeneca rises during Friday’s trading with 5 some percent to 579:50 sek.
”It will because, even if this (Pacific-indication Direkt note) is not as big fraction of patients with the Mystic, this is still a first step and a big market it here as well”, says Johan Unnerus, and adds that his assessment is that the upturn should be ”2-3 per cent”.
Tradingportalen/Agency Directly.
Questions and comments always welcome in the newsroom[at]tradingportalen.com